Blood-brain barrier transport of drugs for the treatment of brain diseases

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 3, 2009, Pages 195-204

  Gabathuler, Reinhard ^a  

^a ANGIOCHEM INC   (Canada)

Author keywords

Blood brain barrier; Brain capillaries; CNS; Delivery; Endothelial cells; Methods; Neurodegenerative diseases; Therapies

Indexed keywords

AMINO ACID TRANSPORTER; ANG 1005; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BACLOFEN; BRADYKININ ANTAGONIST; CARMUSTINE; CERE 120; CHIMERIC PROTEIN; COTARA; DIPHTHERIA TOXOID CRM197; DOXORUBICIN; GLUCOSE TRANSPORTER 1; INSULIN RECEPTOR; IODINE TENASCIN MONOCLONAL ANTIBODY 81C6 I 131; LENTIVIRUS VECTOR; LIPOSOME; LOBRADIMIL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NEURADIAB; NEUROLEPTIC AGENT; NEUROTROPHIC FACTOR; PACLITAXEL; PROPOFOL; TP 38; TRANSFERRIN RECEPTOR; TRANSMEMBRANE DOMAIN PROTEIN 30A; TROJAN HORSE LIPOSOME; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONTINUOUS INFUSION; CONVECTION ENHANCED DELIVERY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; ENDOTHELIUM CELL; GLIOMA; HUMAN; INTRACRANIAL TUMOR; LIPOPHILICITY; MEMBRANE DAMAGE; MOLECULAR SIZE; NONHUMAN; OSMOTIC STRESS; REVIEW; SPASTICITY; SYSTEMIC DISEASE; TRANSCYTOSIS; ULTRASOUND;

EID: 70349492713     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709788680652     Document Type: Review

References (95)

1. Jain, K.K. Drug delivery in central nervous system disorders, technology, companies and markets. Jain Pharmabiotechnology Report, 2007.
2. Ehrlich, P. Das Sauerstoff-Bedurfnis des Organismus: Eine Farbenanalytische Studie. Hirschwald: Berlin, 1885.
3. Shapiro, W.R.; Carpenter, S.P.; Roberts, K.; Khan, J.S. (131)IchTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin. Biol. Ther., 2006, 6, 539-45.
4. Weaver, M.; Laske, D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neuro-Oncol., 2003, 65, 3-13.
5. Mesri, E.A.; Kreitman, R.J.; Fu, Y.-M.; Epstein, S.E.; Pastan, I. Heparin-binding transforming growth factor a-pseudomonas exotoxin A. J. Biochem., 1993, 258, 4853-62.
6. Kunwar, S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir. Suppl., 2003, 88, 105-11.
7. Vandergrift, W.A.; Patel, S.J.; Nicholas, J.S.; Varma, A.K. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg. Focus., 2006 20(4), E10.
8. Blasberg, R.G.; Patlak, C.; Fenstermacher, J.D. Intrathecal chemotherapy: brain tissue profiles after ventriculo-cisternal perfusion. J. Pharmacol. Exp. Ther., 1975, 195, 73-83.
9. Pardridge, W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx., 2005, 2, 3-14.
10. Brennan, P.M.; Whittle, I.R. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br. J. Neurosurg., 2008, 22, 508-19.
11. Pardridge, W.M. Drug targeting to the brain. Pharmacol. Res., 2007, 24, 1733-44.
12. Mohapel, P.; Frielingsdorf, H.; Haggblad, J.; Zachrisson, O.; Brundin, P. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxidopamine lesions. Neuroscience, 2005, 132, 767-76.
13. Fung, L.K.; Ewend, M.J.; Sills, A.; Sipos, E.P.; Thompson, R.; Watts, M.; Colvin, O.M.; Brem, H.; Saltzman, W.M. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res., 1998, 58, 672-84.
14. 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology, 2008, 10, 182-189
15. Gill, S.S.; Patel, N.K.; Hotton, G.R.; O'Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.J.; Svendsen, C.N.; Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 2003, 9, 589-93.
16. Lang, A.E.; Gill, S.; Patel, N.K.; Lozano, A. Nutt, J.G.; Penn, R.; Brooks, D.J.; Hotton, G.; Moro, E.; Heywood, P.; Brodsky, M.A.; Burchiel, K.; Kelly, P.; Dalvi, A.; Scott, B.; Stacy, M.; Turner, D.; Wooten, V.G.; Elias, W.J.; Laws, E.R.; Dhawan, V.; Stoessl, A.J.; Matcham, J.; Coffey, R.J.; Traub, M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol., 2006, 59, 459-66.
17. Marks, W.J.; Jr.; Ostrem, J.L.; Verhagen, L.; Starr, P.A.; Larson, P.S.; Bakay, R.A.E.; Taylor, R.; Cahn-Weiner, D.A.; Stoessel, A.J.; Olanow, C.W.; Bartus, R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adenovirus-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol., 2008, 7, 400-8.
18. Kroll, R.A.; Neuwelt, E.A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery, 1998, 42, 1083-99.
19. Doolittle, N.D.; Miner, M.E.; Hall, W.A.; Siegal, T.; Hanson, E.J.; Osztie, E.; McAllister, L.D.; Bubalo, J.S.; Kraemer, D.F.; Fortin, D.; Nixon, R.; Muldoon, L.L.; Neuwelt, E.A. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer, 2000, 88, 637-47.
20. Fortin, D.; Gendron, C.; Boudrias, M.; Garant, M.-P. Enhanced, chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer, 2007, 109, 751-60.
21. Hynynen, K.; McDannold, N.; Vykhodtseva, N.; Jolesz, F.A. Noninvasive MR Imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology, 2001, 220, 640-6.
22. Hynynen, K.; McDannold, N.; Vykhodtseva, N.; Raymond, S.; Weissleder, R.; Jolesz, F.A.; Sheikov, N. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J. Neurosurg., 2006, 105, 445-54.
23. Kinoshita, M.; McDannold, N.; Jolesz, F.A.; Hynynen, K. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem. Biophys. Res. Comm., 2006, 340, 1085-90.
24. Borlongan, C.V.; Emerich, D.F. Facilitation of drug entry into the CNS via transient permeation of blood-brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res. Bull., 2003, 60, 297-306.
25. Dean, R.L.; Emerich, D.F.; Hasler, B.P.; Bartus, R.T. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Neuro-Oncology, 1999, 1, 268-74.
26. Alavijeh, M.S.; Hoffmann, P.M.; Roe, M.D.; Palmer A.M. Delivery and assessment of potential central nervous system therapeutics across the blood-brain barrier. Cerense Article Drug Deliv., 2007.
27. Erdlenbruch, B.; Alipour, M.; Fricker, G.; Miller, D.S.; Kugler, W.; Eibl, H.; Lakomek, M. Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br. J. Pharmacol., 2003, 140, 1201-10.
28. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discoveryand development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26.
29. Seelig, A. The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J. Mol. Neurosci., 2007, 33, 32-41.
30. Batrakova, E.V.; Kabanov, A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Res., 2008, 130, 98-106.
31. Kabanov, A.V.; Batrakova, E.V.; Miller, D.W. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Deliv. Rev., 2003, 55, 151-64.
32. Qu, X.; Khutoryanskiy, V.V.; Stewart, A.; Rahman. A.; Papahadjopoulos-Sternberg. B.; Dufes. C.; McCarthy. D.; Wilson. C.G.; Lyons. R.; Carter. K.C.; Schatzlein. A.; Uchegbu. I.F. Carbohydrate-based micelle clusters which enhance hydrophobic drug availability by up to 1 order of magnitude. Biomacromolecules, 2006, 7, 3452-9.
33. Allen, D.D.; Lockman, P.R.; Roder, K.E.; Dwoskin, L.P.; Crooks, P.A. Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J. Pharmacol. Exp. Ther., 2003, 304, 1268-74.
34. Jefferies, W.A.; Gabathuler, R.; Rothenberger, S.; Food, M.; Kennard M.L. Pumping iron in the '90s. Trends Cell. Biol., 1996, 6, 223-8.
35. Pardridge, W.M. BBB drug targeting: the future of brain drug development. Mol. Interv., 2003, 3, 90-105.
36. Coloma, M.J.; Lee, H.J.; Kurihara, A.; Landaw, E.M.; Boado, R.J.; Morrison, S.L.; Pardridgr, W.M. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res., 2000, 17, 266-74.
37. Jones, A.R.; Shusta, E.V. Blood-brain barrier transport of therapeutics via receptor mediation. Pharm. Res., 2007, 24, 1759-71.
38. Boado, R.J.; Zhang, Y.; Zhang, Y.; Pardridge, W.M. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng., 2007, 97, 1376-86.
39. Zhang, Y.; Pardridge, W.M. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res., 2006, 1111, 227-9.
40. Bickel, U.; Yoshikawa, T.; Pardridge, W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev., 2001, 46, 247-79.
41. Xia, C.-F.; Boado, R.J.; Pardridge, W.M. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol. Pharmacol., 2008.
42. Xia, C.-F.; Zhang, Y; Zhang, Y.; Boado, R.J.; Pardridge, W.M. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm. Res., 2007, 24, 2309-16.
43. Zhang Y.; Pardridge W.M. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J. Pharmacol. Exp. Ther., 2005, 313, 1075-81.
44. Boado, R.J.; Zhang, Y.; Zhang, Y.; Wang, Y.; Pardridge, W.M. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol. Bioeng., 2007, 100, 387-96.
45. Boado, R.J.; Zhang, Y.; Zhang, Y.; Xia, C.-F.; Pardridge, W.M. Fusion antibody for Alzheimer's Disease with bi-directional transport across the blood-brain barrier and Abeta fibril disaggregation. Bioconj. Chem., 2007, 18, 447-55.
46. Pardridge, W.M. shRNA and siRNA delivery to the brain. Adv. Drug Deliv. Rev., 2007, 59, 141-52.
47. Ulbrich, K.; Herbert, E.; Kreuter, J. Transferrin- and transferrin-receptor monoclonal antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm., 2008, 71 (2), 251-6.
48. Moos, T.; Morgan, E.H. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol. Neurobiol., 2001, 20, 77-95.
49. Gosk, S.; Vermehren, C.; Storm, G.; Moos, T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab., 2004, 24, 1193-204.
50. Hertz, J.; Strickland, D.K. LRP: a multifunctional scavenger and signalling receptor. J. Clin. Invest., 2001, 108, 779-84.
51. Kounnas, M.Z.; Moir, R.D.; Rebeck, G.W.; Bush, A.I.; Argraves, W.S.; Tanzi, R.E.; Hyman, B.T.; Strickland, D.K. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation. Cell, 1995, 82, 331-40.
52. Yoon, I.-S.; Chen, E.; Busse, T.; Repetto, E.; lakshmana, M.K.; Koo, E.H.; Kang, D.E. Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway. FASEB J., 2007, 21, 2742-52.
53. Rebeck, G.W.; Reiter, J.S.; Strickland, D.K.; Hyman, B.T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron, 1993, 11, 575-80.
54. Bu, G.; Maksymovitch, E.A.; Nerbonne, J.M.; Schwartz, A.L. Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. J. Biol. Chem., 1994, 269, 18521-8.
55. Wolf, G.G.; Lopes, M.B.S.; VandenBerg, S.R.; Gonias, S.L. Characterization and immunohistochemical localization of α2-macroglobulin receptor (Low-density lipoprotein receptor-related protein) in human brain. Am. J. Pathol., 1992, 141, 37-42.
56. Moestrup, S.K.; Gliemann, J.; Pallesen, G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res., 1992, 269, 375-82.
57. Yamamoto, M.; Ikeda, K.; Ohshima, K.; Tsugu, H.; Kimura, H.; Tomonaga, M. Increased expression of low density lipoprotein receptor-related protein/α2-macroglobulin receptor in human malignant astrocytomas. Cancer Res., 1997, 57, 2799-805.
58. Kreuter, J. Application of nanoparticles for the delivery of drugs to the brain. Int. Congr. Ser., 2005, 1277, 85-94.
59. Kreuter, J.; Ramge, P.; Petrov, V.; Hamm, S.; Gelperina, S.E.; Engelhardt, B.; Alyautdin, R.; von Briesen, H.; Begley, D.J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res., 2003, 20, 409-16.
60. Steiniger, S.C.J.; Kreuter, J.; Khalansky, A.S.; Skidan, I.N.; Bobruskin, A.I.; Smirnova, Z.S.; Severin, S.E.; Uhl, R.; Kock, M.; Geigerand, K.D.; Gelperina, S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer, 2004, 109, 759-67.
61. Olivier, J.-C. Drug transport to brain with targeted nanoparticles. NeuroRx, 2005, 2, 108-19.
62. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticles-bound drugs across the blood-brain barrier. J. Drug Target., 2002, 10, 317-25.
63. Jefferies, W.A.; Food, M.; Gabathuler, R.; Rothenberger, S.; Yamada, T.; McGeer, P.L. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res., 1996, 712, 122-6.
64. Food, M.; Rothenberger, S.; Gabathuler, R.; Haidl, I.D.; Reid, G.; Jefferies, W.A. Transport and expression in human melanomas of a transferrin like glycosylphosphatidylinositol-anchored proteins. J. Biol. Chem., 1994, 269, 3034-40.
65. Demeule, M.; Poirier, J.; Jodoin, J.; Bertrand, Y.; Desrosiers, R.R.; Dagenais, C.; Nguyen, T.; Lanthier, J.; Gabathuler, R.; Kennard, M.L.; Jefferies, W.A.; Karkan, D.; Tsai, S.; Fenart, L.; Cecchelli, R.; Beliveau, R. High transcytosis of melanotransferrin (p97) across the blood-brain barrier. J. Neurochem., 2002, 83, 924-33.
66. Gabathuler, R.; Arthur, G.; Kennard, M.L.; Chen, Q.; Tsai, S.; Yang, J.; Schoorl, W.; Vitalis, T.Z.; Jefferies, W.A. Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood-brain barrier. Int. Congr. Ser., 2005, 1277, 171-84.
67. Karkan, D.; Pfeifer, C.; Vitalis, T.Z.; Arthur, G.; Ujiie, M.; Chen, Q.; Tsai, S.; Kolaitis, G.; Gabathuler, R.; Jefferies, W.A. A unique carrier for delivery of therapeutical compounds beyond the blood-brain barrier. PLoS ONE, 2008, 3, e2469.
68. Pan, W.; Kastin, A.J.; Zankel, T.C.; van Kerkhof, P.; Terasaki, T.; Bu, G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell. Sci., 2004, 117, 5071-8.
69. Migliorini, M.M.; Behre, E.H.; Brew, S.; Ingham, K.C.; Strickland, D.K. Allosteric modulation of ligand binding to low density lipoprotein receptor-related protein by the receptor-associated protein requires critical lysine residues within the carboxy-terminal domain. J. Biol. Chem., 2003, 278, 17986-92.
70. Prince, W.S.; McCormick, L.M.; Wendt, D.J.; Fitzpatrick, P.A.; Schwartz, K.L.; Aguilera, A.I.; Koppaka, V.; Christianson, T.M.; Vellard, M.C.; Pavloff, N.; Lemontt, J.F.; Qin, M.; Starr, C.M.; Bu, G.; Zankel, T.C. Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and α-L-iduronidase or acid α-glucosidase. J. Biol. Chem., 2004, 279, 35037-46.
71. Spencer, B.J.; Verma, I.M. Targeted delivery of proteins across the blood-brain barrier. Proc. Natl. Acad. Sci. USA, 2007, 104, 7594-9.
72. Demeule, M.; Regina, A.; Che, C.; Poirier, J.; Nguyen, T.; Gabathuler, R.; Castaigne, J.-P.; Beliveau, R. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther., 2008, 324, 1064-72.
73. Demeule, M.; Currie, J.-C.; Bertrand, Y.; Che C.; Nguyen, T.; Regina, A.; Gabathuler, R.; Castaigne, J.-P.; Beliveau, R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J. Neurochem., 2008, 106, 1534-44.
74. Gabathuler, R.; Demeule, M.; Regina, A.; Che, C.; Thomas, F.; Abulrob, A.; Smith, Q.R.; Stanimirovic, D.; Beliveau, R.; Castaigne, J.-P. ANG1005, paclitaxel conjugated to the angiopep brain transport vector for the treatment of brain cancer: preclinical studies. Eur. J. Cancer Suppl., 2008, 6, 39.
75. Gabathuler, R.; Demeule, M.; Regina, A.; Che, C.; Lockman, P.R.; Thomas, F.; Gaasch, J.; Thorsheim, H.; Abulrob, A.; Smith, Q.R.; Stanimirovic, D.; Beliveau, R.; Castaigne, J.-P. A new drug, ANG1005, a conjugate of paclitaxel and angiopep peptide vector, is able to cross the blood-brain barrier for the treatment of brain cancers. Neuro-Oncology, 2008, 10, 784.
76. Smith, Q.R. A review of blood-brain barrier transport techniques. Methods Mol. Med., 2003, 89, 193-208.
77. Takasato, Y.; Rapoport, S.I.; Smith, Q.R. An in situ brain perfusion techniques to study cerebrovascular transport in the rat. Am. J. Physiol., 1984, 247, H484-93.
78. Regina, A.; Demeule, M.; Che, C.; Lavallee, I.; Poirier, J.; Gabathuler, R.; Beliveau, R.; Castaigne, J.-P. Antitumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol., 2008, 155, 185-97.
79. Bichat, F.; Demeule, M.; Lawrence, B.; Raguin, O.; Sourzat, B.; Gabathuler, R.; Castaigne, J.-P.; Genne P. Enhanced drug delivery to brain tumours with a new paclitaxel-peptide conjugate. Eur. J. Cancer Suppl., 2008, 6, 45.
80. Gaillard, P.J.; Brink, A.; de Boer, A.G. Diphteria toxin receptor-targeted brain drug delivery. Int. Congr. Ser., 2005, 1277, 185-95.
81. Raab, G.; Klagsbrun, M. Heparin-binding EGF like growth factor. Biochim. Biophys. Acta, 1997, 1333, F179-99.
82. Fenart, L.; Cecchelli, R. Protein transport in cerebral endothelium. In vitro transcytosis of transferrin. Methods Mol. Med., 2003, 89, 277-90.
83. Kageyama, T.; Ohishi, M.; Miyamoto, S.; Mizushima, H.; Iwamoto, R.; Mekada, E. Diphteria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its antitumorigenic activity. J. Biochem., 2007, 142, 95-104.
84. Abulrob, A.; Sprong, H.; Bergen en Henegouwen, P.V.; Stanimirovic, D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem., 2005, 95, 1201-14.
85. Tanha, J.; Dubuc, G.; Hirama, T.; Narang, S.A.; MacKenzie, C.R. Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties. J. Immunol. Methods, 2002, 263, 97-109.
86. Muruganandam, A.; Tanha, J.; Narang, S.; Stanimirovic, D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J., 2002, 16, 240-2.
87. Tanha, J.; Muruganandam, A.; Stanimirovic, D. Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol. Med., 2003, 89, 435-49.
88. Banks, W.A.; Akerstrom, V.; Kastin, A.J. Adsorptive endocytosis mediates the passage of HIV-1 across the blood-brain barrier: evidence for a post-internalization coreceptor. J. Cell. Sci., 1998, 111, 533-40.
89. Paulusma, C.C.; Folmer, D.E.; Ho-Mok, K.S.; de Wart, D.R.; Hilarius, P.M.; Verhoeven, A.J.; Elferink, R.P.J. ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology, 2008, 47, 268-78.
90. Wender, P.A.; Mitchell, D.J.; Pattabiraman, K.; Pelkey, E.T.; Steinman, L.; Rothbard, J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. USA, 2000, 97, 13003-8.
91. Temsamani, J.; Rousselle, C.; Rees, A.R.; Scherrmann, J.-M. Vector-mediated drug delivery to the brain. Exp. Opin. Biol. Ther., 2001, 1, 773-82.
92. Liu, L.; Guo, K.; Lu, J.; Venkatraman, S.S.; Luo, D.; Ng, K.C.; Ling, E.-A.; Moochhala, S.; Yang, Y.-Y. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials, 2008, 29, 1509-17.
93. Pham, W.; Zhao B.-Q.; Lo E.H.; Medarova, Z.; Rosen, B.; Moore, A. Crossing the blood-brain barrier: a potential application of myristoylated polyarginine for in vivo neuroimaging. Neuroimage, 2005, 28, 287-92.
94. Kumar, P.; Wu, H.; McBride, J.L.; Jung, K.-E.; Kim, M.H.; Davidson, B.L.; Lee, S.K.; Shankar, P.; Manjunath, N. Transvascular delivery of small interfering RNA to the central nervous system. Nature, 2007, 448, 33-40.
95. Lockman, P.R.; Koziara, J.M.; Mumper, R.J.; Allen, D.D. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target., 2004, 12, 635-41.